Teva debuts first generic Lamictal

Israel-headquartered Teva Pharmaceutical says that it has commenced commercial shipment of its generic version of Lamictal (lamotrigine) tablets, 25mg, 100mg, 150mg and 200mg in the USA.

Teva's lamotrigine tablets are the AB-rated generic equivalent of GlaxoSmithKline's Lamictal, and are indicated as adjunctive therapy in the treatment of partial seizures and the generalized seizures of Lennox-Gastaut syndrome, for conversion to monotherapy in adults with partial seizures who are taking certain other antiepileptic agents, and for maintenance treatment of bipolar I disorder. The brand products had annual sales of around $2.2 billion in the USA for the 12 months ended March 31, based on IMS sales data.

In February 2005, GSK and Teva entered into an agreement to settle patent litigation under which the former granted Teva the exclusive right to manufacture and sell a generic version of Lamictal during the six-month pediatric exclusivity which ends on January 22, 2009.